Loading...
XNYS
PEN
Market cap12bUSD
Oct 08, Last price  
317.52USD
1D
0.37%
1Q
-0.18%
Jan 2017
397.68%
IPO
693.80%
Name

Penumbra Inc

Chart & performance

D1W1MN
XNYS:PEN chart
P/E
70.39
P/S
8.91
EPS
4.51
Div yield, %
—
Shrs. gr., 5y
1.90%
Rev. gr., 5y
20.16%
Revenues
1.40b
+17.50%
73,141,00088,848,000125,510,000186,095,000263,317,000333,764,000444,938,000547,405,000560,412,000747,590,000847,133,0001,058,522,0001,194,615,0001,403,665,000
Net income
178m
+1,168.11%
1,958,0004,099,0002,245,0002,365,00014,814,0004,657,0006,601,00048,458,000-15,702,0005,284,000-2,002,00090,954,00014,012,000177,687,000
CFO
239m
+41.66%
-3,396,000-6,389,000-22,279,000-12,807,00012,691,00028,808,00026,652,000-33,242,0009,502,000-55,661,00097,333,000168,481,000238,663,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Related entities

Subsidiaries
CROSSMED S.P.A.

Key people

Chief Financial Officer · since 2019
James Pray
President, International · since 2015
Robert D. Evans
Executive Vice President, General Counsel, Secretary · since 2008
Lynn D. Rothman
Executive Vice President, Chief Business Officer · since 2015
Lambert Shiu
Chief Accounting Officer · since 2019
Johanna Roberts
Executive Vice President, General Counsel, Secretary · since 2018
Arani Bose
Chief Innovator, Director · since 2015
Adam Elsesser
Chairman of the Board, Chief Executive Officer · since 2019
Don W. Kassing
Presiding Independent Director · since 2015
Janet Leeds
Independent Director · since 2019
Bridget O'Rourke
Independent Director · since 2017
Independent Director · since 2017
IPO date
Sep 18, 2015
Employees
3,900
Domiciled in
US
Incorporated in
US
Legal address
C/O Incorporating Services, Ltd.
3500 South Dupont Highway
Dover, DE 19901
US
Headquarters
One Penumbra Place
Alameda, CA 94502
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT